CREDIT SUISSE FIRST BOSTON 13D/13G Filings for UroGen Pharma Ltd. (URGN)

CREDIT SUISSE FIRST BOSTON 13D and 13G filings for UroGen Pharma Ltd.:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Shares have been adjusted for stock splits.
Time period
Reported
DateTime		 Transaction
Date		 Type Company
Symbol		 Filed By
Symbol		 Shares Owned
% Owned		 Shares Vs. Prev Report View
2022-02-14
1:44 pm
Sale		 2021-12-31 13G UroGen Pharma Ltd.
URGN		 CREDIT SUISSE FIRST BOSTON 1,085,749
4.840%		 -35,322decrease
(-3.15%)		 Filing
2021-02-12
4:03 pm
Purchase		 2020-12-31 13G UroGen Pharma Ltd.
URGN		 CREDIT SUISSE FIRST BOSTON 1,121,071
5.070%		 1,121,071increase
(New Position)		 Filing